Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue

Stock Track

06/24

Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.

The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.

Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1120285849"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120285849\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120285849?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120285849","market":"nz","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-24 10:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1120285849","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120285849","pubTimestamp":1782269074,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股赛道|Telix Pharmaceuticals盘中飙升9.62%，得益于强劲的管线和商业影像收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}